TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16902792
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methylprednisolone injected intramuscularly
Study: 9017565
Drug: Histories of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histories of violence, use of drugs, or demographic characteristics
Study: 1705921
Drug: Future oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future oriented hypnotic imagery
Study: 18587620
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg SR, BID)
Study: 16998453
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (3 x 1000 mg/day for 8 days)
Study: 16998453
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x 50 mg/day of glucose for 8 days)
Study: 15151735
Drug: Oxytocin 10
Normalized name: oxytocin 10 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 10 IU IV infusion
Study: 11283917
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg zoledronic acid
Study: 11283917
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg zoledronic acid
Study: 11346861
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg pamidronate
Study: 11283917
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg zoledronic acid
Study: 11283917
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including 2.0 mg and 4.0 mg zoledronic acid, and 90 mg pamidronate)
Study: 9276357
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus immediate LHRH agonist (androgen suppression)
Study: 2885122
Drug: All beta-adrenoceptor
Normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beta-adrenoceptor antagonists (except pindolol)
Study: 2885122
Drug: All beta-adrenoceptor
Normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beta-adrenoceptor antagonists
Study: 30612482
Drug: Betamethasone (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (intramuscular injection of 12 mg in two doses with an interval of 24 hours)
Study: 30306310
Drug: HPV vaccination
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccination post treatment
Study: 27753551
Drug: Sub-dissociative dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-dissociative dose (0.2 mg/kg) of IV ketamine
Study: 20142823
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplement (MMS)
Study: 19329405
Drug: Calcium 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 162 mg
Study: 15996074
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/day)
Study: 10233206
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release verapamil p.o. (240 mg) administered in the morning (08:00 h)
Study: 10233206
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release verapamil p.o. (240 mg) administered in the evening (20:00 h)
Study: 10233206
Drug: Deuterated verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterated verapamil i.v. (10 mg) administered in the morning
Study: 10233206
Drug: Deuterated verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterated verapamil i.v. (10 mg) administered in the evening
Study: 1924426
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg E5
Study: 1924426
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg E5
Study: 1924426
Drug: E5 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 (2.5 mg/kg and 7.5 mg/kg)
Study: 24445092
Drug: 2.4 mL
Normalized name: 2.4 ML Imfinzi 50 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mL contrast agent
Study: 24445092
Drug: 4.8 mL
Normalized name: Elyxyb 120 MG in 4.8 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 mL contrast agent
Study: 24445092
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL contrast agent
Study: 20447259
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ) 400 mg 3 x per day and amoxicillin (AMX) 500 mg 3 x per day for 14 days
Study: 15990456
Drug: pegylated IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated IFN α‐2b plus a standard or weight‐based dose of ribavirin
Study: 7725889
Drug: Nefopam hydrochloride
Normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam hydrochloride (20 mg) in group A
Study: 7725889
Drug: Meperidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (50 mg) in group A
Study: 7725889
Drug: Nefopam hydrochloride
Normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam hydrochloride (10 mg) in group B
Study: 7725889
Drug: Nefopam hydrochloride
Normalized name: nefopam hydrochloride
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam hydrochloride (20 mg) in group C
Study: 1904749
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 400 mg
Study: 1904749
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 1200 mg
Study: 6100880
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg once-a-day
Study: 24170766
Drug: 2-hour suspension
Normalized name: dextroamphetamine 2 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour suspension of basal insulin
Study: 20647511
Drug: Standard aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aqueous cream
Study: 10528035
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily for 52 weeks
Study: 9495581
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg i.v. twice a day for five days
Study: 7803739
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of protamine (Group I)
Study: 24357473
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (<0.8 g/(kg · d))
Study: 24357473
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein intake (0.8-<1.0 g/(kg · d))
Study: 24357473
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (1.0-1.2 g/(kg · d))
Study: 12486283
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose 6‐methylprednisolone
Study: 8679359
Drug: ondansetron with
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron with dexamethasone (4 mg and 8 mg, respectively)
Study: 21811829
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml warm water instillation (30 °C)
Study: 21344803
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection (ITDI), administered once every week for a maximum of three sessions
Study: 15643512
Drug: Paclitaxel (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (70 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (35 mg/m2) on days 1 and 8 every 3 weeks (GCP)
Study: 15643512
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2 on days 1, 8, 15) and cisplatin (70 mg/m2 on day 2 every 4 weeks (GC)
Study: 7867444
Drug: HD‐Ara‐C (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐Ara‐C (1.0 g/m2)
Study: 7867444
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HD‐Ara‐C therapy)
Study: 31282394
Drug: Spinal decompression
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal decompression therapy (SDT) with core stabilization exercises (CSE)
Study: 31300012
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 mL/kg) in high P/F subgroup (> 150 mmHg)
Study: 31300012
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 mL/kg) in low P/F subgroup (≤ 150 mmHg)
Study: 25906559
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with transperineal injection of 200 IU BTX-A
Study: 25906559
Drug: Transperineal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal injection of 200 IU BTX-A
Study: 24143017
Drug: Coarse CAPs
Normalized name: silica, trimethylsilyl capped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse CAPs (200 µg/m(3))
Study: 24143017
Drug: Fine CAPs
Normalized name: silica, trimethylsilyl capped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine CAPs (250 µg/m(3))
Study: 19664769
Drug: Meperidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (50 mg)
Study: 19664769
Drug: Valethamate bromide
Normalized name: valethamate bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valethamate bromide (16 mg)
Study: 9417487
Drug: Parenteral selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral selenium supplementation (week 1: twice 500 micrograms daily, week 2: once 500 micrograms, week 3: three times 100 micrograms sodium selenite)
Study: 9417487
Drug: Parenteral selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral selenium supplementation
Study: 7679737
Drug: Naltrexone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (12.5 mg)
Study: 26135853
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg)
Study: 7679737
Drug: Hydromorphone (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.75, 1.5 and 3 mg)
Study: 7679737
Drug: Pentazocine (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (15, 30 and 60 mg)
Study: 30833436
Drug: Irinotecan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (150 mg/m2) administered intravenously over 90 min on day 1, and S-1 (80 mg/m2) given orally in two divided doses from days 1 to 14 of a 21 day cycle.
Study: 21047625
Drug: Non-search paradigm
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-search paradigm testing with an agent demonstrating a rattling object
Study: 17984395
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs) including olanzapine, quetiapine fumarate, risperidone
Study: 17984395
Drug: Placebo (representing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (representing a 'watchful waiting' treatment strategy)
Study: 14638565
Drug: Weekly patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly patient self-management with phenprocoumon
Study: 14638565
Drug: Weekly management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly management at an anticoagulation clinic with phenprocoumon
Study: 14638565
Drug: Weekly management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly management with acenocoumarol
Study: 10823572
Drug: Mandatory vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory vaccination program for HCWs (intramuscular half dose from 1990 to 1995, intradermal from 1983 to 1989)
Study: 1626674
Drug: Lignocaine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine at a dose of 0.2 mg.kg‐1
Study: 6093979
Drug: High-dose CAV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CAV (HD-CAV) - cyclophosphamide 1200 mg/m2, doxorubicin 70 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21
Study: 6093979
Drug: Conventional-dose CAV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CAV + VP-16 (CAV-VP) - cyclophosphamide 1000 mg/m2, doxorubicin 40 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21 with VP-16 100 mg/m2 on days 1-3 and 21-23
Study: 3742319
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg PO the night prior to surgery and 300 mg IV 30 minutes prior to anaesthesia induction (Part 1)
Study: 29550085
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor
Study: 29550085
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT)
Study: 29550085
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin plus DAPT
Study: 24171782
Drug: Individualized acupuncture
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized acupuncture point prescriptions, 20 sessions over four weeks.
Study: 24171782
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group, no treatment for 24 weeks, followed by 20 acupuncture treatments for free.
Study: 18312057
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day for 10 weeks
Study: 17025273
Drug: Darbepoetin alfa,
Normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa, subcutaneous doses of 0.5 microg/kg every week to 15 microg/kg every 3 weeks
Study: 17025273
Drug: Darbepoetin alfa,
Normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa, intravenous and subcutaneous doses of 2.25 microg/kg every week and 6.75 microg/kg every 3 weeks
Study: 17025273
Drug: Darbepoetin alfa,
Normalized name: DARBEPOETIN ALFA,RECOMBINANT
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa, subcutaneous doses
Study: 10945387
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus infusions of 1,000 IU AT III every 4 h for 4 days (total dose: 30,000 IU AT III)
Study: 10945387
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 250 IU AT III/h for 4 days (total dose: 30,000 IU AT III)
Study: 10945387
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (Intermittent bolus and Continuous infusion)
Study: 1532964
Drug: Lithium succinate
Normalized name: lithium succinate
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium succinate ointment (8%)
Study: 31000320
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement with HMB 1200mg, l‐glutamine 7000mg, and l‐arginine 7000mg administered once or twice per day for 14‐28 days preoperatively.
Study: 1708969
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg/24 h in three divided doses)
Study: 25475116
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nitisinone
Study: 25475116
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nitisinone
Study: 25475116
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nitisinone
Study: 25475116
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nitisinone
Study: 11591618
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg oral dose)
Study: 11339516
Drug: meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 15 mg
Study: 8630640
Drug: piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam 20 mg
Study: 7849250
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 100 mg/day
Study: 7849250
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg thrice daily added to thiazide and placebo regimens
Study: 16547387
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes mellitus group
Study: 12381983
Drug: Traditional chiropractic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional chiropractic treatment (nonintervention group)
Study: 8536868
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments for inflammatory bowel disease (specific interventions not detailed in the abstract)
Study: 2180981
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human GH treatment
Study: 543202
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day Perhexilinmaleat
Study: 543202
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day Perhexilinmaleat
Study: 25633470
Drug: Modifying Phonation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifying Phonation Intervals (MPI) treatment
Study: 25633470
Drug: Prolonged speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged speech treatment
Study: 15951310
Drug: 4% dimeticone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% dimeticone lotion
Study: 15188980
Drug: Expressed breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressed breast milk (EBM) 5 ml
Study: 15188980
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (DW) 5 ml (placebo)
Study: 11480129
Drug: Pioglitazone (Actos),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (Actos), specific dosage and duration not mentioned
Study: 2694853
Drug: Better chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Better chemotherapy regimens and bone marrow transplantation
Study: 30388950
Drug: Guided mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided mindfulness practice (daily using an audio CD)
Study: 28637246
Drug: Psilocybin (0.215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0.215 mg/kg p.o.)
Study: 15836710
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg once daily
Study: 19741494
Drug: Ephedrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (10 mg)
Study: 16500392
Drug: Scheduled maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled maintenance treatment with infliximab (3 doses)
Study: 16500392
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment with infliximab (single dose)
Study: 16500392
Drug: Scheduled maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled maintenance treatment with infliximab
Study: 16500392
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment with infliximab
Study: 16500392
Drug: Scheduled infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scheduled infliximab maintenance therapy
Study: 11716203
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of prednisolone p.o. for 1 week
Study: 11716203
Drug: 1600 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 microg of inhaled budesonide daily for 1 week
Study: 11716203
Drug: 1600 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 microg of inhaled budesonide daily for 3 weeks (after initial treatment)
Study: 31859197
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen (systemic therapy)
Study: 30854836
Drug: Guided implant
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided implant surgery
Study: 23332456
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS-MPH) 18, 36, or 54 mg/day
Study: 21654267
Drug: Febuxostat 20
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20 mg/d for 7 days
Study: 15569270
Drug: Inflaban (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflaban (100 mg) suppository
Study: 15569270
Drug: Voltaren (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren (100 mg) suppository